Bank of America Cuts Harmony Biosciences (NASDAQ:HRMY) Price Target to $28.00

Harmony Biosciences (NASDAQ:HRMY) had its price objective trimmed by Bank of America from $32.00 to $28.00 in a report published on Wednesday,Benzinga reports. The brokerage currently has an underperform rating on the stock.

A number of other research analysts have also weighed in on HRMY. Mizuho set a $50.00 price objective on shares of Harmony Biosciences in a research note on Thursday, February 19th. Deutsche Bank Aktiengesellschaft lowered shares of Harmony Biosciences from a “buy” rating to a “hold” rating and set a $31.00 target price on the stock. in a report on Monday. Weiss Ratings reiterated a “hold (c)” rating on shares of Harmony Biosciences in a research note on Monday, December 29th. UBS Group downgraded Harmony Biosciences from a “buy” rating to a “neutral” rating and increased their price objective for the stock from $43.00 to $46.00 in a research note on Wednesday, February 11th. Finally, HC Wainwright restated a “buy” rating on shares of Harmony Biosciences in a report on Wednesday, December 3rd. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Harmony Biosciences presently has an average rating of “Hold” and an average price target of $42.67.

Harmony Biosciences Trading Down 1.8%

Shares of Harmony Biosciences stock opened at $28.54 on Wednesday. The stock has a market capitalization of $1.65 billion, a PE ratio of 10.53, a price-to-earnings-growth ratio of 0.36 and a beta of 0.84. Harmony Biosciences has a 52 week low of $25.52 and a 52 week high of $40.87. The stock has a 50 day moving average price of $36.01 and a two-hundred day moving average price of $34.07. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.72 and a current ratio of 3.60.

Harmony Biosciences (NASDAQ:HRMY) last issued its earnings results on Tuesday, February 24th. The company reported $0.38 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.46). Harmony Biosciences had a return on equity of 19.86% and a net margin of 18.29%.The firm had revenue of $243.78 million during the quarter, compared to the consensus estimate of $240.04 million. During the same quarter in the prior year, the business earned $0.85 earnings per share. Harmony Biosciences’s revenue for the quarter was up 21.1% on a year-over-year basis. As a group, equities analysts anticipate that Harmony Biosciences will post 2.43 earnings per share for the current fiscal year.

Insider Buying and Selling at Harmony Biosciences

In related news, CEO Jeffrey M. Dayno sold 25,933 shares of the business’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $40.11, for a total transaction of $1,040,172.63. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Sandip Kapadia sold 3,746 shares of the stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $37.15, for a total value of $139,163.90. Following the sale, the chief financial officer directly owned 24,521 shares in the company, valued at $910,955.15. This trade represents a 13.25% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 50,640 shares of company stock worth $1,932,256. Company insiders own 23.60% of the company’s stock.

Institutional Investors Weigh In On Harmony Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Robeco Institutional Asset Management B.V. boosted its position in shares of Harmony Biosciences by 0.6% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 47,085 shares of the company’s stock valued at $1,762,000 after acquiring an additional 298 shares during the period. Thrivent Financial for Lutherans lifted its stake in Harmony Biosciences by 1.2% in the 3rd quarter. Thrivent Financial for Lutherans now owns 28,639 shares of the company’s stock worth $789,000 after purchasing an additional 348 shares in the last quarter. Nebula Research & Development LLC boosted its holdings in Harmony Biosciences by 2.0% in the 2nd quarter. Nebula Research & Development LLC now owns 17,403 shares of the company’s stock valued at $550,000 after purchasing an additional 348 shares during the period. Amalgamated Bank grew its position in shares of Harmony Biosciences by 3.8% during the 3rd quarter. Amalgamated Bank now owns 11,328 shares of the company’s stock valued at $312,000 after purchasing an additional 417 shares in the last quarter. Finally, Ameritas Investment Partners Inc. increased its holdings in shares of Harmony Biosciences by 12.0% in the second quarter. Ameritas Investment Partners Inc. now owns 4,466 shares of the company’s stock worth $141,000 after purchasing an additional 479 shares during the period. 86.23% of the stock is currently owned by institutional investors.

Key Stories Impacting Harmony Biosciences

Here are the key news stories impacting Harmony Biosciences this week:

• Positive Sentiment: HC Wainwright kept a “Buy” rating and a $55 price target and published a long-range FY2030 EPS projection (which reinforces an upbeat long-term thesis), supporting upside potential despite near-term cuts. HC Wainwright research on HRMY
• Neutral Sentiment: An aggregate coverage note reported HRMY has an average analyst rating of “Moderate Buy,” indicating mixed consensus sentiment across the sell-side. This tempers the impact of individual downgrades but leaves the stock sensitive to further model changes. Average analyst rating report
• Negative Sentiment: Zacks Research downgraded HRMY from “strong-buy” to “hold,” reducing near-term buy-side conviction and likely contributing to selling pressure. Zacks downgrade
• Negative Sentiment: Truist Securities downgraded HRMY to “Hold” citing patent trial developments — a direct legal/intellectual property risk that can materially affect exclusivity and future revenue, and is a key reason for today’s weakness. Truist downgrade after patent trial developments
• Negative Sentiment: HC Wainwright also lowered near-term EPS forecasts across Q1–Q4 2026 (multiple cuts to quarterly estimates), signaling weaker near-term profitability expectations that can pressure the stock until guidance or sales trends rebound. HC Wainwright EPS revision details

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.